Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Cancer and multiple sclerosis in the era of disease-modifying treatments.

Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, Debouverie M, de Seze J, Wiertlevsky S, Heinzlef O, Tourbah A, Fromont A, Frenay M.

J Neurol. 2011 Jul;258(7):1304-11. doi: 10.1007/s00415-011-5929-9. Epub 2011 Feb 4.

PMID:
21293872
2.

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.

Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, Hahn T, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

J Neurol Sci. 2016 Nov 15;370:13-17. doi: 10.1016/j.jns.2016.09.005. Epub 2016 Sep 9.

PMID:
27772741
3.

Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.

Lebrun C, Debouverie M, Jeannin S, Pittion-Vouyovitch S, Bayreuther C, Berthier F.

Mult Scler. 2008 Aug;14(7):933-9. doi: 10.1177/1352458508091369. Epub 2008 Jun 23.

PMID:
18573824
4.

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.

Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Wiertlevski S, Defer G, Gout O, Berthier F, Danzon A.

Mult Scler. 2008 Apr;14(3):399-405. doi: 10.1177/1352458507083625.

PMID:
18420778
5.

Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.

Chouhfeh L, Kavak KS, Teter BE, Weinstock-Guttman B.

Mult Scler Relat Disord. 2015 May;4(3):228-33. doi: 10.1016/j.msard.2015.02.004. Epub 2015 Feb 27.

PMID:
26008939
6.

[CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment].

Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, Defer G, Berthier F; Club Francophone de la Sclérose en Plaques.

Rev Neurol (Paris). 2007 Jan;163(1):38-46. Review. French.

PMID:
17304171
7.
8.

Parenthood and immunomodulation in patients with multiple sclerosis.

Hellwig K, Haghikia A, Gold R.

J Neurol. 2010 Apr;257(4):580-3. doi: 10.1007/s00415-009-5376-z. Epub 2009 Nov 21.

PMID:
19936821
9.

[The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].

Jernas Ł, Piorunek T, Tokarz E, Wygladalska-Jernas H, Kozubski W, Michalak S.

Przegl Lek. 2012;69(10):750-2. Polish.

PMID:
23421025
10.

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.

Zhang T, Tremlett H, Leung S, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell TL, Stadnyk K, Yu BN, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2016 Apr 5;86(14):1287-95. doi: 10.1212/WNL.0000000000002543. Epub 2016 Mar 4.

11.

Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.

Degli Esposti L, Piccinni C, Sangiorgi D, Perrone V, Aledda L, Marrosu MG, Lombardo F.

Neurol Sci. 2017 Apr;38(4):589-594. doi: 10.1007/s10072-016-2806-4. Epub 2017 Jan 11.

PMID:
28078563
12.

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.

Bonafede MM, Johnson BH, Wenten M, Watson C.

Clin Ther. 2013 Oct;35(10):1501-12. doi: 10.1016/j.clinthera.2013.07.330.

PMID:
24139422
13.

Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.

Evans C, Marrie RA, Zhu F, Leung S, Lu X, Melesse DY, Kingwell E, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2016 Jul;8:78-85. doi: 10.1016/j.msard.2016.05.006. Epub 2016 May 7.

14.

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G.

Neurology. 1996 Jun;46(6):1607-12.

PMID:
8649558
15.

Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.

Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H.

Mult Scler Relat Disord. 2015 Jan;4(1):75-82. doi: 10.1016/j.msard.2014.09.214. Epub 2014 Oct 7.

PMID:
25787057
16.

[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No].

Edan G.

Rev Neurol (Paris). 2013 Nov;169(11):864-8. doi: 10.1016/j.neurol.2013.08.004. Epub 2013 Oct 11. French.

PMID:
24125462
17.

Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.

Reynolds MW, Stephen R, Seaman C, Rajagopalan K.

J Med Econ. 2010 Mar;13(1):90-8. doi: 10.3111/13696990903579501.

PMID:
20078189
18.

Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.

Oleen-Burkey M, Cyhaniuk A, Swallow E.

J Med Econ. 2013;16(3):397-406. doi: 10.3111/13696998.2013.764309. Epub 2013 Jan 22.

PMID:
23301877
19.

A new treatment era in multiple sclerosis: clinical applications of new concepts.

Edan G, Leray E.

J Neurol Sci. 2011 Jul 15;306(1-2):170-2. doi: 10.1016/j.jns.2010.09.018. Epub 2010 Oct 16.

PMID:
20951999
20.

Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.

Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D.

Cardiovasc Ther. 2014 Apr;32(2):33-9. doi: 10.1111/1755-5922.12049.

PMID:
24119301

Supplemental Content

Support Center